Our new client is focused on transforming Lab innovations of India into market commercialization. Aagami has been selected to take such off...
Published : 01 Apr 2019
Read MoreOur new Korean client has developed E. coli Monophosphoryl Lipid A, a novel adjuvant. This is directly produced in genetically engineered E. coli and ...
Published : 05 Mar 2019
Read MoreAagami will support development of a breakthrough life-saving drug to treat alcohol poisoning of a client from Israel. Along with our associates we sh...
Published : 28 Feb 2019
Read MoreIn keeping up with the annual tradition, Aagami is participating in JP Morgan Healthcare conference and BioTech Showcase January 2019. Both event...
Published : 02 Dec 2018
Read MoreAs part of its extensive networking and representation of Aagami clients Mr. Dinesh Jain, Founder CEO of Aagami, attended Bio-Europe 2018 - Copenhagen...
Published : 09 Nov 2018
Read MoreIn a yet another client win, Aagami received an assignment from an Innovative company who has developed an Abuse Deterrent and Life Saving Drug to add...
Published : 03 Aug 2018
Read MoreApart from promoting Aagami Inc, Dinesh Jain, the Founder CEO will be representing 2 clients at the The BIO International Convention 2018.The industry...
Published : 01 Jun 2018
Read MoreAagami Inc. has been appointed to support its new California based client’s Next-Generation PEG technology and assets with 53 Patents. The Tech...
Published : 10 May 2018
Read MoreHappy with the ongoing work, this existing Aagami client has given an additional assignment to Aagami. This time the assignment is to support the clie...
Published : 09 May 2018
Read MoreA US based company with consolidated annual sales of around US$700M has appointed Aagami to support their expansion in India, Middle East and other co...
Published : 07 Mar 2018
Read More